Drug · CHEMBL42
CLOZAPINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CLOZAPINE. Drugs and targets, record CHEMBL42. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL42
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
Clozapina, Clozapine (caraco), Clozapine (clozaril), Clozapine (fazaclo), Clozapine (ivax), Clozapine (mylan), Clozapine (teva), Clozapine (udl), Clozapine (versacloz), Clozapine resolution mixture, HF 1854, HF-1854, Leponex, NSC-757429
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 11 diseases, from ATC, DailyMed, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | Dopamine D2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1813 |
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials79
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02404155 | Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN) | 274 | 2023-01-31 | clozapine | Its name | ClinicalTrials.gov | |
| NCT00158223 | Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia | Phase 4 | 76 | 2015-04-09 | clozapine | Its name | ClinicalTrials.gov |
| NCT00981526 | Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia | Phase 4 | 66 | 2018-06-19 | clozapine | Its name | ClinicalTrials.gov |
| NCT00056498 | Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine | Phase 4 | 65 | 2012-07-16 | clozapine | Its name | ClinicalTrials.gov |
| NCT01639872 | Clozapine for Cannabis Use in Schizophrenia | Phase 4 | 49 | 2019-12-26 | clozapine | Its name | ClinicalTrials.gov |
| NCT00042224 | Electroconvulsive Therapy in Clozapine Refractory Schizophrenia | Phase 1/2 | 39 | 2015-10-15 | clozapine | Its name | ClinicalTrials.gov |
| NCT00345033 | Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia | Phase 4 | 38 | 2012-09-13 | clozapine | Its name | ClinicalTrials.gov |
| NCT00498550 | Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual | Phase 4 | 31 | 2012-01-19 | clozapine | Its name | ClinicalTrials.gov |
| NCT01654601 | A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg | Phase 1 | 28 | 2014-03-14 | clozapine | Its name | ClinicalTrials.gov |
| NCT00001656 | Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders | Phase 4 | 25 | 2011-04-12 | clozapine | Its name | ClinicalTrials.gov |
1 to 10 of 79
See all 79 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Risperidone vs Placebo: serious adverse events | 1 of 30 | 2 of 35 | 65 | NCT00056498 | Trial comparisons |
| Pimozide vs Placebo: serious adverse events | 0 of 25 | 0 of 28 | 53 | NCT00158223 | Trial comparisons |
| Clozapine vs Risperidone: deaths from any cause | 0 of 23 | 0 of 24 | 47 | NCT01639872 | Trial comparisons |
| Clozapine vs Risperidone: serious adverse events | 3 of 23 | 3 of 24 | 47 | NCT01639872 | Trial comparisons |
| A: Experimental vs B: Placebo: serious adverse events | 0 of 22 | 0 of 22 | 44 | NCT00981526 | Trial comparisons |
| Electroconvulsive Therapy With Medication vs Medication Monotherapy: serious adverse events | 0 of 20 | 0 of 19 | 39 | NCT00042224 | Trial comparisons |
| Clozapine vs Treatment as Usual: serious adverse events | 4 of 15 | 4 of 16 | 31 | NCT00498550 | Trial comparisons |
| Aripiprazole vs Placebo: serious adverse events | 0 of 16 | 0 of 14 | 30 | NCT00345033 | Trial comparisons |
| A Group vs B Group: serious adverse events | 1 of 14 | 0 of 14 | 28 | NCT01654601 | Trial comparisons |
| Olanzapine Group vs Clozapine Group: serious adverse events | 1 of 13 | 2 of 12 | 25 | NCT00001656 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials96
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials7
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 3 | 0 | ConductCognition |
| Trail Making Test B | 3 | 0 | ConductCognition |
| Verbal Learning | 3 | 0 | ConductCognition |
| Symbol Coding | 2 | 0 | ConductCognition |
| Paced Visual Serial Addition Test | 1 | 0 | ConductCognition |
| Point Subtraction Aggression Task | 1 | 0 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL42
GET https://conductscience.org/api/drugs/v1/CHEMBL42/trials?page=2